Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
